Akebia Therapeutics, Inc.

NasdaqCM AKBA

Akebia Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

Akebia Therapeutics, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Akebia Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -32.40%, a 32.67% change year over year.
Akebia Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -48.12%, a 8.30% change year over year.
Akebia Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2020 was -52.47%, a -68.13% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: AKBA

Akebia Therapeutics, Inc.

CEO	Mr. John P. Butler MBA
IPO Date	March 20, 2014
Location	United States
Headquarters	245 First Street
Employees	167
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Clinical Trials Drugstores & Retail Pharmacies Non-Alcoholic Beverages

Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years